Health Equity and Secukinumab for Severe Psoriasis in New Zealand.
Аннотация
BACKGROUND/
OBJECTIVES
The only funded indication in New Zealand between October 2018 and April 2021 for the biologic secukinumab, an interleukin-17A antibody, was severe psoriasis. This unique period of limited availability of secukinumab allowed the evaluation of who received it and health equity.
METHODS
Anonymised dispensing data were obtained from the New Zealand Ministry of Health and matched with the New Zealand deprivation index, ethnicity and census data.
RESULTS
Compared to the most socio-economically deprived, the least deprived were significantly more likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 4.00 (3.29-4.71) and 6.56 (5.61-7.51) p < 0.0001. Compared to European ethnicity, Māori, Pacific peoples and Asian were less likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 6.30 (5.81-6.79), 3.27 (2.56-3.99), 3.31 (2.28-4.33), 4.33 (3.48-5.19) p < 0.0001 all groups.
CONCLUSIONS
Between October 2018 and April 2021, the data suggest that the dispensing of secukinumab was inequitable. Those having severe psoriasis and being socio-economically disadvantaged or of Māori, Pacific and Asian compared to European ethnicity, were significantly less likely to have received secukinumab. Dermatologist workforce shortages in New Zealand are likely to compound the problem.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.